thalidomide has been researched along with Lichen Myxedematosus in 28 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Scleromyxedema is a chronic disease with high morbidity and mortality and no definitive therapeutic guidelines." | 2.66 | Scleromyxedema treatment: a systematic review and update. ( Bachour, J; El Gemayel, M; Haber, R, 2020) |
| "Scleromyxedema is a rare mucinous deposition disorder that shares clinical features with scleroderma but has important distinguishing features in clinical presentation and major organ complications that should be recognized." | 2.50 | Scleromyxedema. ( Hummers, LK, 2014) |
| "Scleromyxedema is a rare idiopathic fibromucinous disorder characterized by a generalized papular and sclerodermoid cutaneous eruption." | 1.72 | Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins. ( Chen, QY; Wang, SS; Xiang, LH, 2022) |
| "Myopathy in scleromyxedema is a poorly recognized syndrome among neurologists and can mimic idiopathic and connective tissue disease-associated inflammatory myopathy." | 1.51 | An unusual presentation of scleromyxedema as inflammatory myopathy. ( Nair, M; Nair, SS; Poyuran, R; Vysakha, KV, 2019) |
| "Treatment with thalidomide has proved to be effective in the management of these patients." | 1.40 | Scleromyxedema without paraproteinemia. ( Abarzúa, AA; Giesen, LF; González, SB; Sandoval, MO, 2014) |
| "The scleromyxedema is a rare condition characterized by hyperproliferation of fibroblasts with increased dermal deposition of mucin and frequently associated with monoclonal gammopathy of undetermined significance." | 1.39 | [Response to thalidomide in scleromyxedema]. ( Caballero Escuti, G; Kurpis, M; Pascualini, MF; Ruiz Lascano, A; Valente, E, 2013) |
| "Thalidomide was introduced but was discontinued after 2 months due to side effects." | 1.36 | [Efficacy of intravenous immunoglobulin in the treatment of scleromyxoedema]. ( Cardot-Leccia, N; Lacour, JP; Ortonne, JP; Passeron, T; Perrin, C; Sillard, L, 2010) |
| "Scleromyxedema is a rare disorder characterized by mucin deposits in the dermis and monoclonal gammopathy." | 1.35 | Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema. ( Arpaci, F; Ataergin, S; Demiriz, M; Ozet, A, 2008) |
| "We present a patient with a severe scleromyxedema with cutaneous, gastrointestinal, hematologic, and neurologic manifestations." | 1.35 | Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature. ( Blanco, M; Efthimiou, P, 2008) |
| "Treatment with thalidomide was started and great improvement of the lesion was noted as shown by a quality of life questionnaire similar to those used in rheumatoid arthritis." | 1.34 | Scleromyxedema: successful treatment with thalidomide in two patients. ( Amini-Adle, M; Balme, B; Dalle, S; Thieulent, N; Thomas, L, 2007) |
| "Treatment of scleromyxedema is limited by the lack of long-term results, toxicity and significant adverse side effects." | 1.33 | Scleromyxedema, a positive effect with thalidomide. ( Fien, S; Jacob, SE; Kerdel, FA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (32.14) | 29.6817 |
| 2010's | 16 (57.14) | 24.3611 |
| 2020's | 3 (10.71) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, SS | 1 |
| Chen, QY | 1 |
| Xiang, LH | 1 |
| Khandkar, C | 1 |
| Vaidya, K | 1 |
| Penglase, R | 1 |
| Cai, K | 1 |
| Shin, JS | 1 |
| Hunyor, I | 1 |
| Keech, A | 1 |
| McGill, N | 1 |
| Haber, R | 1 |
| Bachour, J | 1 |
| El Gemayel, M | 1 |
| Pipa, S | 1 |
| Sá, J | 1 |
| Mondragão, A | 1 |
| Marinho, A | 1 |
| Vysakha, KV | 1 |
| Poyuran, R | 1 |
| Nair, SS | 1 |
| Nair, M | 1 |
| Pascualini, MF | 1 |
| Caballero Escuti, G | 1 |
| Valente, E | 1 |
| Kurpis, M | 1 |
| Ruiz Lascano, A | 1 |
| Brunet-Possenti, F | 1 |
| Hermine, O | 1 |
| Marinho, E | 1 |
| Crickx, B | 1 |
| Descamps, V | 1 |
| Abarzúa, AA | 1 |
| Giesen, LF | 1 |
| Sandoval, MO | 1 |
| González, SB | 1 |
| Devos, T | 1 |
| Thiessen, S | 1 |
| Cuyle, PJ | 1 |
| Meersseman, W | 1 |
| Delforge, M | 1 |
| Abarzúa, A | 1 |
| Sandoval, M | 1 |
| González, S | 1 |
| Giesen, L | 1 |
| Hummers, LK | 1 |
| Cao, XX | 1 |
| Wang, T | 1 |
| Liu, YH | 1 |
| Zhou, DB | 1 |
| Li, J | 1 |
| Atci, T | 1 |
| Yazganoglu, KD | 1 |
| Yonal, I | 1 |
| Ekinci, AP | 1 |
| Kaplan, SG | 1 |
| Babuna, G | 1 |
| Besisik, S | 1 |
| Baykal, C | 1 |
| Ataergin, S | 1 |
| Arpaci, F | 1 |
| Demiriz, M | 1 |
| Ozet, A | 1 |
| Laimer, M | 1 |
| Namberger, K | 1 |
| Massone, C | 1 |
| Koller, J | 1 |
| Emberger, M | 1 |
| Pleyer, L | 1 |
| Hintner, H | 1 |
| Greil, R | 1 |
| Sillard, L | 1 |
| Passeron, T | 1 |
| Cardot-Leccia, N | 1 |
| Perrin, C | 1 |
| Lacour, JP | 1 |
| Ortonne, JP | 1 |
| Le Moigne, M | 1 |
| Mazereeuw-Hautier, J | 1 |
| Bonnetblanc, JM | 1 |
| Astudillo, L | 1 |
| D'Incan, M | 1 |
| Bessis, D | 1 |
| Thomas, L | 2 |
| Debarbieux, S | 1 |
| Ammoury, A | 2 |
| Lamant, L | 2 |
| Paul, C | 1 |
| do Prado, AD | 1 |
| Schmoeller, D | 1 |
| Bisi, MC | 1 |
| Piovesan, DM | 1 |
| Dias, FS | 1 |
| Staub, HL | 1 |
| Bos, R | 1 |
| de Waal, EG | 1 |
| Kuiper, H | 1 |
| Hazenberg, BP | 1 |
| Vellenga, E | 1 |
| Yeung, CK | 1 |
| Loong, F | 1 |
| Kwong, YL | 1 |
| Guarenti, I | 1 |
| Sebastiani, V | 1 |
| Pinto, G | 1 |
| de Souza, PR | 1 |
| de Almeida, H | 1 |
| Jacob, SE | 1 |
| Fien, S | 1 |
| Kerdel, FA | 1 |
| Thyssen, JP | 1 |
| Zachariae, C | 1 |
| Menné, T | 1 |
| Amini-Adle, M | 1 |
| Thieulent, N | 1 |
| Dalle, S | 1 |
| Balme, B | 1 |
| Efthimiou, P | 1 |
| Blanco, M | 1 |
| Martins, A | 1 |
| Paiva Lopes, MJ | 1 |
| Tavares Belo, R | 1 |
| Rodrigues, JC | 1 |
| Wu, MY | 1 |
| Hong, JB | 1 |
| Yang, CC | 1 |
| Hu, SL | 1 |
| Liao, YH | 1 |
| Peter, LM | 1 |
| Chiavassa-Gandois, H | 1 |
| Paul, CF | 1 |
2 reviews available for thalidomide and Lichen Myxedematosus
| Article | Year |
|---|---|
Scleromyxedema treatment: a systematic review and update.
Topics: Bortezomib; Humans; Prospective Studies; Retrospective Studies; Scleromyxedema; Thalidomide | 2020 |
Scleromyxedema.
Topics: Boronic Acids; Bortezomib; Humans; Immunoglobulins, Intravenous; Pyrazines; Scleromyxedema; Thalidom | 2014 |
26 other studies available for thalidomide and Lichen Myxedematosus
| Article | Year |
|---|---|
Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins.
Topics: Exanthema; Female; Humans; Immunoglobulins, Intravenous; Middle Aged; Paraproteinemias; Rare Disease | 2022 |
Rare case of infiltrative cardiomyopathy secondary to scleromyxoedema.
Topics: Adult; Cardiomyopathies; Female; Humans; Immunoglobulins, Intravenous; Magnetic Resonance Imaging; P | 2020 |
Scleromyxoedema: the importance of physical examination.
Topics: Administration, Intravenous; Adult; Biopsy; Diagnosis, Differential; Fibroblasts; Humans; Immunoglob | 2018 |
An unusual presentation of scleromyxedema as inflammatory myopathy.
Topics: Adult; Biopsy; Diagnosis, Differential; Drug Therapy, Combination; Female; Glucocorticoids; Humans; | 2019 |
[Response to thalidomide in scleromyxedema].
Topics: Female; Humans; Immunosuppressive Agents; Middle Aged; Paraproteinemias; Scleromyxedema; Thalidomide | 2013 |
Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema.
Topics: Administration, Oral; Adult; Biopsy, Needle; Disease Progression; Dose-Response Relationship, Drug; | 2013 |
Scleromyxedema without paraproteinemia.
Topics: Adolescent; Humans; Immunosuppressive Agents; Male; Paraproteinemias; Scleromyxedema; Thalidomide | 2014 |
Long-term follow-up in a patient with the dermato-neuro syndrome treated with high-dose melphalan, thalidomide, and intravenous immunoglobulins for more than 7 years.
Topics: Adult; Follow-Up Studies; Humans; Immunoglobulins, Intravenous; Male; Melphalan; Nervous System Dise | 2014 |
Letter to the editor.
Topics: Humans; Immunosuppressive Agents; Male; Scleromyxedema; Thalidomide | 2014 |
Successful treatment of scleromyxedema with melphalan and dexamethasone followed by thalidomide maintenance therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Immunogl | 2016 |
Lichen myxedematosus: a case series focusing on clinical features, disease associations, and management.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Combined Modality Therapy; Diagnosis, Differential; Fema | 2017 |
Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunogl | 2008 |
Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema.
Topics: Antineoplastic Agents; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Human | 2009 |
[Efficacy of intravenous immunoglobulin in the treatment of scleromyxoedema].
Topics: Adrenal Cortex Hormones; Drug Resistance; Female; Humans; Immunoglobulin G; Immunoglobulin lambda-Ch | 2010 |
[Clinical characteristics, outcome of scleromyxoedema: a retrospective multicentre study].
Topics: Adrenal Cortex Hormones; Adult; Aged; Biopsy; Combined Modality Therapy; Diagnosis, Differential; Fe | 2010 |
Scleromyxedema with monoclonal gammopathy and neurological involvement: recovery from coma after plasmapheresis?
Topics: Brain Diseases; Coma; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Myeloablative | 2012 |
Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema.
Topics: Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Dexamethasone; | 2011 |
Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Middle Aged; Neopla | 2012 |
Successful treatment of scleromyxedema with oral thalidomide.
Topics: Adult; Humans; Hyperpigmentation; Immunosuppressive Agents; Male; Paraproteinemias; Scleromyxedema; | 2013 |
Scleromyxedema, a positive effect with thalidomide.
Topics: Angiogenesis Inhibitors; Female; Follow-Up Studies; Humans; Middle Aged; Paraproteins; Scleromyxedem | 2006 |
Successful treatment of scleromyxedema using thalidomide.
Topics: Humans; Immunosuppressive Agents; Male; Middle Aged; Scleromyxedema; Thalidomide | 2006 |
Scleromyxedema: successful treatment with thalidomide in two patients.
Topics: Adult; Aged; Cell Proliferation; Female; Fibroblasts; Follow-Up Studies; Humans; Immunosuppressive A | 2007 |
Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature.
Topics: Aged; Drug Therapy, Combination; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosu | 2008 |
Scleromyxedema--thalidomide therapy.
Topics: Aged; Female; Humans; Immunosuppressive Agents; Scleromyxedema; Skin; Thalidomide | 2008 |
Scleromyxedema with myopathy was successfully treated by thalidomide.
Topics: Biopsy; Female; Humans; Middle Aged; Muscular Diseases; Scleromyxedema; Thalidomide | 2009 |
Scleromyxoedema with associated peripheral neuropathy: successful treatment with thalidomide.
Topics: Aged; Dermatologic Agents; Female; Humans; Peripheral Nervous System Diseases; Scleromyxedema; Thali | 2008 |